A Two-part, Phase II trial Assessing the Effects of Inhaled SNG001 in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Two-part, Phase II trial Assessing the Effects of Inhaled SNG001 in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Chronic obstructive pulmonary disease; Viral infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Synairgen
  • Most Recent Events

    • 07 Feb 2018 According to a Synairgen media release, the second part of this trial will bridge the end of the 2017/2018 winter/spring virus season and the 2018 virus season which starts in the autumn.
    • 07 Feb 2018 According to a Synairgen media release, the first part of the trial is scheduled to complete in March 2018.
    • 07 Feb 2018 According to a Synairgen media release, the first patients have been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top